Shark Tank's Kevin Harrington Leads Crowdfunding Campaign For Psycheceutical Bioscience (OTCPK: BWVI)

Shark Tank’s Kevin Harrington thinks safe psychedelic medicines without the “trip” are the future of mental health care, and has put his support behind Psycheceutical - Click Here To Invest

Psycheceutical Bioscience, Inc BWVI is a biotechnology company developing precision dosing technologies designed to cross the blood-brain barrier for the next generation of therapeutic medicines. The company is currently focused on psychedelic medicines, with the goal of making these promising drugs safer and more affordable – while eliminating hallucinogenic effects and toxicity. With the potential to revolutionize mental health care treatment, Psycheceutical seems to have been gaining interest across the scientific and investment communities. Kevin Harrington, an “Original Shark” from the hit TV show Shark Tank, invested in Psycheceutical last year and joined as the company’s Strategic Advisor to provide expertise on the company’s growth and development. 

As the creator of the infomercial and pioneer of the As Seen on TV brand, Harrington’s business ventures have launched more than 1,000 products and produced over $6 billion in global sales.

Harrington recently spoke with Benzinga about his involvement in the bioscience company and why he sees psychedelics as such an important industry. 

Mental Health Breakthroughs With Psychedelics: Promising Medicines And A Potentially Good Investment 

Harrington shared that current mental health treatments using decades-old technology are proving to be ineffective, and with so many people struggling with their mental health, there is a real need for innovation in treatments. Harrington believes that Psycheceutical really stands out against the crowd, especially when it comes to the company’s patented delivery methods designed to increase the safety and accessibility of psychedelic medicines while removing the “trippy” effects.

With 52.9 million adults living with mental illness in the U.S. alone and current treatments for mental health still using 1980s technology, millions of people have been left with no viable options to treat these debilitating diseases. Psychedelic medicines have shown much promise in recent studies for treating mental health disorders but need precise dosing control more like pharmaceutical medicines before they can be made available to the general public.

Psycheceutical is removing these barriers by employing two next-generation patented delivery technologies designed to increase the safety and efficacy of psychedelic compounds: NeuroDirect™ non-systemic delivery technology and Janus particle systemic delivery nanotechnology. This long-awaited precision dosing technology is intended to deliver psychedelic compounds directly to targeted receptor sites in the brain within minutes – while bypassing the stomach and liver, eliminating hallucinogenic effects and vastly reducing exposure to drug toxicities and side effects.

Psycheceutical Has Gotten Positive Feedback From the Scientific Community, And Investors Seem To Be Taking Notice 

Psycheceutical’s first drug in their pipeline, NeuroDirect ketamine topical for the treatment of PTSD, is already seeing positive results in observational clinical data. A peer-reviewed study published by Drug Development & Delivery shared that more than 80% of 100 PTSD patients who tried the NeuroDirect ketamine topical found it effective at treating their symptoms, with no patients experiencing psychogenic effects like hallucinations. The company also recently released positive first cohort dosing results of their phase I clinical trial of NeuroDirect ketamine, which showed the topical application as safe and well-tolerated. Life Sciences Review has named the company a 2023 Top 10 Biotech Startup, and the company was listed as one of “7 Psychedelic Stocks to Watch” by U.S. News & World Report.

With all the recent acclaim, the company just launched a crowdfunding campaign through Wefunder to raise funds to conduct more research and bring more drugs through the clinical trial process. Harrington is calling on small investors to join him in investing in Psycheceutical to advance psychedelic medicines and help solve the global mental health care crisis.

“When I see a new industry emerging, I try to pick the companies that are highly scalable. In psychedelics, that’s going to be the companies focused on safety and efficacy like Psycheceutical. Psycheceutical has patented delivery systems designed to remove the hallucinogenic effects of psychedelics and deliver them with targeted dosing, which makes these compounds available to the mainstream,” said Harrington. “Now, with Psycheceutical’s crowdfunding offering, even the small investor can own a piece of this quickly growing bioscience company and benefit from the huge opportunity of the company’s strong intellectual property in the psychedelic space.”

Buying shares in early-development startups is a proven way to potentially earn exponential returns. Usually, that means buying at the pre-IPO (pre-Initial Public Offering) stage, however, these investments have considerable risks, and it’s unknown how the company will actually perform once it goes public, if ever. Psycheceutical is already publicly listed on the OTC Market and has the backing of major investors like Harrington. 

The psychedelic drug market will likely be a key player in mental health treatments in the coming years, and innovative companies like Psycheceutical seem well-positioned to become major players. A recent report from The Business Research Company projected that the global psychedelic drugs market size will grow from $4.2 billion in 2022 to $4.83 billion in 2023 at a compound annual growth rate (CAGR) of 14.9%, and the market size is expected to grow at a CAGR of 14.5% and reach $8.31 billion by 2027. Psycheceutical seems poised to meet the demand for safer, more accessible, and more affordable psychedelic medicines for people struggling with mental health disorders.

To Invest In The Company, Click Here.

Featured photo courtesy of Psycheceutical Bioscience, Inc.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.